CRIS Current Research Information System

GATTI, MILO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 8.406
EU - Europa 5.581
NA - Nord America 5.200
SA - Sud America 509
AF - Africa 235
OC - Oceania 38
Continente sconosciuto - Info sul continente non disponibili 4
AN - Antartide 1
Totale 19.974
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.002
IT - Italia 3.172
CN - Cina 2.308
SG - Singapore 2.306
VN - Vietnam 1.632
HK - Hong Kong 496
NL - Olanda 452
DE - Germania 399
KR - Corea 393
BD - Bangladesh 386
BR - Brasile 361
IN - India 319
SE - Svezia 246
FR - Francia 240
GB - Regno Unito 229
FI - Finlandia 172
RU - Federazione Russa 170
JP - Giappone 154
CA - Canada 113
IE - Irlanda 111
CI - Costa d'Avorio 103
ID - Indonesia 84
AR - Argentina 66
BG - Bulgaria 61
CH - Svizzera 57
ES - Italia 56
MX - Messico 50
PH - Filippine 47
PL - Polonia 46
AT - Austria 45
TH - Thailandia 40
TR - Turchia 34
AU - Australia 33
IQ - Iraq 33
TG - Togo 32
TW - Taiwan 30
ZA - Sudafrica 29
SA - Arabia Saudita 25
UA - Ucraina 23
JO - Giordania 19
PE - Perù 19
PK - Pakistan 19
EC - Ecuador 15
BE - Belgio 14
CO - Colombia 14
NG - Nigeria 14
CL - Cile 12
HR - Croazia 12
PT - Portogallo 12
UZ - Uzbekistan 12
MY - Malesia 11
PY - Paraguay 10
RO - Romania 10
IL - Israele 9
TN - Tunisia 9
AE - Emirati Arabi Uniti 8
JM - Giamaica 8
KE - Kenya 8
LT - Lituania 8
NP - Nepal 8
EG - Egitto 7
GR - Grecia 7
SC - Seychelles 7
VE - Venezuela 7
DZ - Algeria 6
CR - Costa Rica 5
CY - Cipro 5
HU - Ungheria 5
IR - Iran 5
KH - Cambogia 5
MA - Marocco 5
DK - Danimarca 4
NI - Nicaragua 4
NZ - Nuova Zelanda 4
BA - Bosnia-Erzegovina 3
BH - Bahrain 3
BO - Bolivia 3
CZ - Repubblica Ceca 3
ET - Etiopia 3
GT - Guatemala 3
MD - Moldavia 3
OM - Oman 3
PA - Panama 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
SM - San Marino 3
AO - Angola 2
AZ - Azerbaigian 2
CV - Capo Verde 2
EU - Europa 2
GH - Ghana 2
HN - Honduras 2
LB - Libano 2
LV - Lettonia 2
ME - Montenegro 2
MK - Macedonia 2
MT - Malta 2
PR - Porto Rico 2
XK - ???statistics.table.value.countryCode.XK??? 2
AL - Albania 1
Totale 19.945
Salva come PNG Salva come JPEG
Città #
Singapore 1.625
Hefei 866
Ashburn 684
San Jose 474
Hong Kong 471
Bologna 452
Ho Chi Minh City 444
Seoul 367
Hanoi 348
Santa Clara 342
Milan 313
Chandler 256
Rome 232
Beijing 220
Boardman 218
New York 197
Los Angeles 173
Council Bluffs 147
Dallas 142
Lauterbourg 140
Tokyo 122
Princeton 118
Dublin 109
Abidjan 103
Southend 103
Helsinki 99
Fairfield 98
Bengaluru 84
Buffalo 83
Dong Ket 83
Florence 69
Da Nang 68
Turin 68
Naples 66
Sofia 61
Redmond 60
Haiphong 59
Redondo Beach 57
Jakarta 55
Chicago 53
Lappeenranta 53
Seattle 49
Houston 47
São Paulo 46
Genoa 45
Nuremberg 44
Castel Maggiore 41
Frankfurt am Main 39
Toronto 38
Shanghai 35
Munich 34
Bern 33
Verona 33
Lomé 32
London 32
Bari 30
Des Moines 30
Montreal 29
The Dalles 29
Woodbridge 29
Berlin 28
Orem 28
Cambridge 27
Guangzhou 27
Modena 27
Warsaw 27
Vienna 26
Falkenstein 25
Mexico City 25
Wilmington 25
Mumbai 24
Vicenza 24
Palermo 23
Tongling 23
Amsterdam 22
Denver 22
Padua 21
Rimini 21
Boydton 20
Phoenix 20
San Diego 20
San Francisco 20
Tappahannock 20
Atlanta 19
Biên Hòa 19
Bremen 19
Trieste 19
Amman 18
Catania 18
Turku 18
Xi'an 18
Can Tho 17
Quận Bình Thạnh 17
Hải Dương 16
Ann Arbor 15
Baghdad 15
Bangkok 15
Boston 15
Brooklyn 15
Cagliari 15
Totale 11.310
Salva come PNG Salva come JPEG
Nome #
Targeted Therapy of Severe Infections Caused by Staphylococcus aureus in Critically Ill Adult Patients: A Multidisciplinary Proposal of Therapeutic Algorithms Based on Real-World Evidence 369
Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system 318
Impact of a newly established expert clinical pharmacological advice program based on TDM results in tailoring antimicrobial therapies hospital-wide in a tertiary university hospital: findings after the first-year of implementation 316
An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of infection-related ventilator associated complications (IVACs) caused by Enterobacterales in critically ill adult patients 315
Artificial Intelligence model to predict resistances in Gram-negative bloodstream infections 294
Impact of attaining aggressive vs. conservative PK/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysis 262
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-negative bloodstream infections and/or ventilator-associated pneumonia 248
Antimicrobial Dose Reduction in Continuous Renal Replacement Therapy: Myth or Real Need? A Practical Approach for Guiding Dose Optimization of Novel Antibiotics 221
Pharmacokinetic and pharmacodynamic considerations for optimizing antimicrobial therapy used to treat bone and joint infections: an evidence-based algorithmic approach 218
Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams 214
Impact of attaining an aggressive PK/PD target with continuous infusion beta-lactams on the clinical efficacy of targeted therapy of early post-transplant Gram-negative infections in critically ill OLT recipients. An interim analysis of a 3-year prospective, observational, study 208
Management of intra-abdominal infections: recommendations by the Italian council for the optimization of antimicrobial use 202
A descriptive case series of the relationship between maintenance of conservative PK/PD efficacy thresholds of dalbavancin over time and clinical outcome in long-term treatment of staphylococcal osteoarticular infections 201
Assessment of a pk/pd target of continuous infusion beta-lactams useful for preventing microbiological failure and/or resistance development in critically ill patients affected by documented gram-negative infections 201
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems 196
Advances in the therapy of bacterial bloodstream infections 192
Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin-resistant staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and future 191
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam for treating DTR gram-negative infections in a case series of critically ill patients undergoing continuous veno-venous haemodiafiltration (CVVHDF) 190
Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP 189
A pre-post quasi-experimental study of antimicrobial stewardship exploring the impact of a multidisciplinary approach aimed at attaining an aggressive joint pharmacokinetic/pharmacodynamic target with ceftazidime/avibactam on treatment outcome of KPC-producing Klebsiella pneumoniae infections and on ceftazidime/avibactam resistance development 186
Efficacy of a Novel Prophylactic Scheme of Fosfomycin Trometamol in Patients Undergoing Endoscopic Surgery for Benign Prostatic Hyperplasia: Findings from a Prospective Monocentric Single-Arm Study 185
Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing 184
Critical reappraisal of current issues for improving the proper clinical use of the incoming beta-lactam/beta-lactamase inhibitor combinations of tomorrow 182
Tolerability of pulsed high-dose L-AmB as pre-emptive therapy in patients at high risk for intra-abdominal candidiasis: A phase 2 study (LAMBDA study) 178
Real-Time TDM-Guided Optimal Joint PK/PD Target Attainment of Continuous Infusion Piperacillin–Tazobactam Monotherapy Is an Effective Carbapenem-Sparing Strategy for Treating Non-Severe ESBL-Producing Enterobacterales Secondary Bloodstream Infections: Findings from a Prospective Pilot Study 178
Pharmacokinetics/pharmacodynamics of cefiderocol administered by continuous infusion in a case series of critically ill patients with carbapenem-resistant Acinetobacter baumannii infections undergoing continuous venovenous haemodiafiltration (CVVHDF) 177
Breakthrough invasive fungal infection after liver transplantation in patients on targeted antifungal prophylaxis: A prospective multicentre study 177
Impact of a multidisciplinary management team on clinical outcome in ICU patients affected by Gram-negative bloodstream infections: a pre-post quasi-experimental study 175
A Sensitive Liquid Chromatography–Tandem Mass Spectrometry Method for Measuring Fosfomycin Concentrations in Human Prostatic Tissue 173
Feasibility of 24 h continuous-infusion cefiderocol administered by elastomeric pump in attaining an aggressive PK/PD target in the treatment of NDM-producing Klebsiella pneumoniae otomastoiditis 172
Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant Pseudomonas aeruginosa Bloodstream Infections and/or Hospital-Acquired Pneumonia 171
A novel method to evaluate ceftazidime/avibactam therapy in patients with carbapenemase-producing Enterobactericeae (CPE) bloodstream infections 168
Therapeutic drug monitoring of ceftazidime/avibactam: why one leg is not enough to run 168
Impact of Inflammation on Voriconazole Exposure in Critically ill Patients Affected by Probable COVID-19-Associated Pulmonary Aspergillosis 166
The Cytokine Release Syndrome and/or the Proinflammatory Cytokines as Underlying Mechanisms of Downregulation of Drug Metabolism and Drug Transport: A Systematic Review of the Clinical Pharmacokinetics of Victim Drugs of this Drug-Disease Interaction Under Different Clinical Conditions 166
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance 165
Enterococcus faecium bacteraemia: a multicentre observational study focused on risk factors for clinical and microbiological outcomes 164
Implementation and validation of a Bayesian method for accurately forecasting duration of optimal pharmacodynamic target attainment with dalbavancin during long-term use for treating subacute and/or chronic staphylococcal infections 163
Relationship Between Real-time TDM-guided Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam Monotherapy and Microbiologic Outcome in the Treatment of Critically Ill Children With Severe Documented Gram-negative Infections 161
Highly adsorptive removal of cefiderocol during continuous venovenous hemodiafiltration equipped with oXiris filter in an orthotopic liver transplant recipient having septic shock caused by VIM-producing Klebsiella pneumoniae 160
Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis 156
Piperacillin-tazobactam vs. carbapenems for treating hospitalized patients with ESBL-producing Enterobacterales bloodstream infections: a systematic review and meta-analysis 155
A pre-post quasi-experimental study of the impact of TDM-guided aggressive pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftolozane/tazobactam monotherapy in treating severe Pseudomonas aeruginosa infections: A strategy useful for raising the bar? 154
Could an optimized joint pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam be a way to avoid the need for combo therapy in the targeted treatment of deep-seated DTR Gram-negative infections? 153
Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase 153
A descriptive case series of PK/PD target attainment and microbiological outcome in critically ill patients with documented severe XDR Acinetobacter baumannii BSI and/or VAP treated with cefiderocol 150
Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration 148
The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia 148
Relationship between Pharmacokinetic/Pharmacodynamic Target Attainment and Microbiological Outcome in Critically Ill COVID-19 Patients with Documented Gram-Negative Superinfections Treated with TDM-Guided Continuous-Infusion Meropenem 147
Does therapeutic drug monitoring (TDM) of trough concentrations suffice for optimizing preemptive therapy with ganciclovir of cytomegalovirus infections in non-renal solid organ transplant recipients? 147
An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by Pseudomonas aeruginosa and Acinetobacter baumannii in Critically Ill Adult Patients 146
Relationship between adverse drug reactions to antibacterial agents and the Klebsiella pneumoniae carbapenemase-producing (KPC) Klebsiella pneumoniae outbreak: Insight from a pharmacovigilance study 144
A Proof of Concept of the Role of TDM-Based Clinical Pharmacological Advices in Optimizing Antimicrobial Therapy on Real-Time in Different Paediatric Settings 144
Comparative Effectiveness and Safety of Direct Oral Anticoagulants: Overview of Systematic Reviews 142
Continuous versus intermittent infusion of antibiotics in Gram-negative multidrug-resistant infections 142
Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis 142
The European List of Key Medicines for Medical Education: A Modified Delphi Study 140
An innovative population pharmacokinetic/pharmacodynamic strategy for attaining aggressive joint PK/PD target of continuous infusion ceftazidime/avibactam against KPC- and OXA-48- producing Enterobacterales and preventing resistance development in critically ill patients 140
Effect of incremental tazobactam concentrations on the bactericidal activity of piperacillin against ESBL-producing enterobacterales clinical isolates causing bacteraemia 139
Assessing the association between fluoroquinolones and emerging adverse drug reactions raised by regulatory agencies: An umbrella review 139
Clinical efficacy of cefiderocol-based regimens in patients affected by carbapenem-resistant Acinetobacter baumannii infections: a systematic review with meta-analysis 138
Usefulness of a hub and spoke TDM-guided expert clinical pharmacological advice program of dalbavancin for optimizing very long-term curative or suppressive treatment of chronic staphylococcal infections 138
Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors 138
Impact of Inflammatory Burden on Voriconazole Exposure in Oncohematological Pediatric Patients Receiving Antifungal Prophylaxis after Allogeneic HCT 138
Adaptive trials of new antimicrobials for infections with carbapenem-resistant, Gram-negative bacteria 137
Clinical outcome in solid organ transplant recipients affected by COVID-19 compared to general population: a systematic review and meta-analysis 137
Fast and Simple Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Dalbavancin in Long-Term Treatment of Subacute and/or Chronic Infections 135
Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19 135
Assessment of adverse reactions to α-lipoic acid containing dietary supplements through spontaneous reporting systems 134
An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of bsis, cutis, and ciais caused by enterobacterales in critically ill adult patients 133
Fast and Sensitive Analysis of Cefiderocol in Human Plasma Microsamples by Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry for Therapeutic Drug Monitoring 130
Two Comprehensive Liquid Chromatography High-Resolution Mass Spectrometry (UPLC-MS/MS) Multi-Methods for Real-Time Therapeutic Drug Monitoring (TDM) of Five Novel Beta-Lactams and of Fosfomycin Administered by Continuous Infusion 129
Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis 129
The impact of preservation fluid culture on graft site arteritis: a systematic review and metanalysis 128
Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization 128
Successful Treatment of Bacteremia and Ventilator-Associated Pneumonia Caused by KPC/OXA-48-like Klebsiella pneumoniae Co-Producer with a Continuous Infusion of High-Dose Meropenem Plus Fosfomycin Guided by Real-Time Therapeutic Drug Monitoring 128
Real-Time Optimization of Pharmacodynamic Target Attainment at Infection Site during Treatment of Post-Neurosurgical Ventriculitis Caused by Carbapenem-Resistant Gram Negatives with Ceftazidime–Avibactam-Based Regimens: A Report of Two Cases 127
The expert clinical pharmacological advice program for tailoring on real-time antimicrobial therapies with emerging TDM candidates in special populations: how the ugly duckling turned into a swan 125
Population Pharmacokinetic and Pharmacodynamic Analysis of Dalbavancin for Long-Term Treatment of Subacute and/or Chronic Infectious Diseases: The Major Role of Therapeutic Drug Monitoring 124
Quantification of 1,3-β-d-glucan by Wako β-glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study 124
Novel CMY-186 variant conferring cross-resistance to cefiderocol and ceftazidime/avibactam in Klebsiella pneumoniae from a critically ill patient during cefiderocol and ceftazidime/avibactam treatment 123
Suboptimal drug exposure leads selection of different subpopulations of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae in a critically ill patient 123
Reply-Letter to the editor - The valuable support of spontaneous reporting systems in exploring safety profile of dietary supplements 122
Janus kinase inhibitors and coronavirus disease (Covid)‐19: Rationale, clinical evidence and safety issues 122
Fast and Sensitive Method for Simultaneous Quantification of Meropenem and Vaborbactam in Human Plasma Microsamples by Liquid Chromatography-Tandem Mass Spectrometry for Therapeutic Drug Monitoring 122
Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System 121
Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients 120
Quality of care indicators in the MAnageMent of BlOOdstream infections caused by Enterobacteriaceae (MAMBOO-E study): state of the art and research agenda 119
Role of a TDM-guided strategy of isavuconazole for optimizing efficacy/safety outcomes in onco-hematological pediatric patients: a systematic review 118
Impact on clinical outcome of follow-up blood cultures and risk factors for persistent bacteraemia in patients with gram-negative bloodstream infections: a systematic review with meta-analysis 115
Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept 114
Utility of a TDM-Guided Expert Clinical Pharmacological Advice Program for Optimizing the Use of Novel Beta-Lactam/Beta-Lactamase Inhibitor Combinations and Cefiderocol in a Tertiary University Hospital: An Interim Analysis 113
Clinical efficacy of renal dosing adjustments of ceftazidime‐avibactam in patients affected by carbapenem‐resistant Gram‐negative infections: a systematic review and meta‐analysis of observational studies 111
Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections 111
Usefulness of a TDM-Guided Approach for Optimizing Teicoplanin Exposure in the Treatment of Secondary Bloodstream Infections Caused by Glycopeptide-Susceptible Enterococcus faecium 111
Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis 109
Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections 108
Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach for Maximizing the Effectiveness of Monotherapy Even in the Treatment of Critically Ill Patients with Documented Extended-Spectrum Beta-Lactamase-Producing Enterobacterales Bloodstream Infections and/or Ventilator-Associated Pneumonia? 108
Pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam in peritoneal fluid in an orthotopic liver transplant recipient affected by bacteraemic complicated intra-abdominal infection: due to OXA-181-producing Klebsiella pneumoniae 107
Drug Interactions with Contraceptives 107
Totale 16.032
Salva come PNG Salva come JPEG
Categoria #
all - tutte 59.676
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.676
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021149 0 0 0 0 0 0 0 0 0 0 0 149
2021/20221.092 57 1 23 47 87 65 120 127 57 96 230 182
2022/20231.455 97 105 75 181 144 106 95 126 243 84 84 115
2023/20241.469 95 108 99 144 129 160 140 144 100 123 113 114
2024/20254.778 182 455 404 380 548 263 501 238 173 446 435 753
2025/202611.283 968 1.246 1.041 915 854 434 1.426 408 1.647 812 849 683
Totale 20.495